Managing gastrointestinal side-effects and preventing treatment discontinuation with GLP-1 therapies GI symptoms are the most common adverse effects of GLP-1 therapies, with nausea, constipation, diarrhea, and vomiting occurring in around 40 % of patients [11,[30], [31], [32]]
1994 , 23 (1827) H
Moreover, it is recognized to be a pantothenate kinase inhibitor, a long-chain-fatty-acid--CoA ligase inhibitor, a ferroptosis inhibitor, a cardioprotective agent, an antidepressant, and a geroprotector (National Center for Biotechnology Information, 2023g)
Identification of cuproptosis-related gene lipoyltransferase 1 as a promising biomarker in oral squamous cell carcinoma
From 2018 to 2024, 1.8 million unique patients received some type of GLP-1 medication